![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Sunday, February 28, 2021 7:27:05 AM
From another poster- great work Corundum:
“However, it appears they were trying to get the convertible bond holders to change to preferred shares that also were convertible to common stock at $6.50 a share. Since the bonds may have been convertible at $5.85 a share, and in any event are due to be paid out in full on March 31, 2021, I don't know how much actual conversion to preferred shares took place. But even if it was successful, the bondholders were offered boatloads of preferred converts and warrants for more common shares as well.
Which is my point all along -- there is a tremendous overhang of warrants and converts to common stock in the $5.85 to $6.50 range, and these parties may well have already sold these shares short into the market at prices between $8 and $10. If so, these short sales and short positions can never be "squeezed", as some parties elsewhere are advocating. The holders will simply convert to cover.
It would take at least half a day of research into all the KemPharm SEC filings for the past four months related to the capital raise and the restructuring in order to get a better handle on all this. Since I do not plan on investing in this company, I will not be doing it. I recommend that anyone who is planning on investing do the work -- do their own due diligence -- because some of the quantities are frightening.
I am not saying that the company cannot be a success (although their business model is a strange one), I just don't think any pops in the stock on FDA approval will be very sustainable. “
Recent KMPH News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/25/2024 09:13:10 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 06/25/2024 09:11:32 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 04/29/2024 11:49:38 AM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 04/10/2024 08:23:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/10/2024 11:46:20 AM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 04/03/2024 08:17:44 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/03/2024 08:15:21 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 04/01/2024 09:27:49 PM
Glidelogic Corp. Becomes TikTok Shop Partner, Opening a New Chapter in E-commerce Services • GDLG • Jul 5, 2024 7:09 AM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • BNCM • Jul 2, 2024 7:19 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM